186 related articles for article (PubMed ID: 16750231)
1. Miltefosine: issues to be addressed in the future.
Berman J; Bryceson AD; Croft S; Engel J; Gutteridge W; Karbwang J; Sindermann H; Soto J; Sundar S; Urbina JA
Trans R Soc Trop Med Hyg; 2006 Dec; 100 Suppl 1():S41-4. PubMed ID: 16750231
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy in the treatment and control of leishmaniasis.
Alvar J; Croft S; Olliaro P
Adv Parasitol; 2006; 61():223-74. PubMed ID: 16735166
[TBL] [Abstract][Full Text] [Related]
3. [Oral miltefosine to treat leishmaniasis].
Soto J; Soto P
Biomedica; 2006 Oct; 26 Suppl 1():207-17. PubMed ID: 17361856
[TBL] [Abstract][Full Text] [Related]
4. Miltefosine and cutaneous leishmaniasis.
Machado PR; Penna G
Curr Opin Infect Dis; 2012 Apr; 25(2):141-4. PubMed ID: 22248979
[TBL] [Abstract][Full Text] [Related]
5. Miltefosine for visceral leishmaniasis relapse treatment and secondary prophylaxis in HIV-infected patients.
Marques N; Sá R; Coelho F; Oliveira J; Saraiva Da Cunha J; Meliço-Silvestre A
Scand J Infect Dis; 2008; 40(6-7):523-6. PubMed ID: 18584541
[TBL] [Abstract][Full Text] [Related]
6. [Miltefosine: a new remedy for leishmaniasis].
Dorlo TP; Eggelte TA; Beijnen JH; de Vries PJ
Ned Tijdschr Geneeskd; 2006 Dec; 150(49):2697-701. PubMed ID: 17194005
[TBL] [Abstract][Full Text] [Related]
7. Treatment of leishmaniasis with miltefosine: 2008 status.
Berman JJ
Expert Opin Drug Metab Toxicol; 2008 Sep; 4(9):1209-16. PubMed ID: 18721114
[TBL] [Abstract][Full Text] [Related]
8. Miltefosine for Indian visceral leishmaniasis.
Agarwal PK
N Engl J Med; 2003 Feb; 348(9):857-8; author reply 857-8. PubMed ID: 12606744
[No Abstract] [Full Text] [Related]
9. Miltefosine: oral treatment of leishmaniasis.
Soto J; Soto P
Expert Rev Anti Infect Ther; 2006 Apr; 4(2):177-85. PubMed ID: 16597200
[TBL] [Abstract][Full Text] [Related]
10. A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection.
Ritmeijer K; Dejenie A; Assefa Y; Hundie TB; Mesure J; Boots G; den Boer M; Davidson RN
Clin Infect Dis; 2006 Aug; 43(3):357-64. PubMed ID: 16804852
[TBL] [Abstract][Full Text] [Related]
11. Miltefosine for new world cutaneous leishmaniasis.
Soto J; Arana BA; Toledo J; Rizzo N; Vega JC; Diaz A; Luz M; Gutierrez P; Arboleda M; Berman JD; Junge K; Engel J; Sindermann H
Clin Infect Dis; 2004 May; 38(9):1266-72. PubMed ID: 15127339
[TBL] [Abstract][Full Text] [Related]
12. Development of miltefosine for the leishmaniases.
Berman JD
Mini Rev Med Chem; 2006 Feb; 6(2):145-51. PubMed ID: 16472183
[TBL] [Abstract][Full Text] [Related]
13. [Leishmaniasis--oral treatment with hexadecylphosphocholine].
Bommer W; Eibl HJ; Engel KR; Kuhlencord A; Sindermann H; Sundar S; Zappel H
Wien Klin Wochenschr; 2004; 116 Suppl 4():24-9. PubMed ID: 15683039
[TBL] [Abstract][Full Text] [Related]
14. Diffuse cutaneous leishmaniasis responds to miltefosine but then relapses.
Zerpa O; Ulrich M; Blanco B; Polegre M; Avila A; Matos N; Mendoza I; Pratlong F; Ravel C; Convit J
Br J Dermatol; 2007 Jun; 156(6):1328-35. PubMed ID: 17441955
[TBL] [Abstract][Full Text] [Related]
15. Miltefosine--discovery of the antileishmanial activity of phospholipid derivatives.
Croft SL; Engel J
Trans R Soc Trop Med Hyg; 2006 Dec; 100 Suppl 1():S4-8. PubMed ID: 16904717
[TBL] [Abstract][Full Text] [Related]
16. Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis.
Dorlo TP; Balasegaram M; Beijnen JH; de Vries PJ
J Antimicrob Chemother; 2012 Nov; 67(11):2576-97. PubMed ID: 22833634
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of visceral leishmaniasis: efficacy and limits of miltefosine].
Gangneux JP; Marty P
Sante; 2001; 11(4):257-8. PubMed ID: 11861203
[No Abstract] [Full Text] [Related]
18. Successful treatment with miltefosine of disseminated cutaneous leishmaniasis in a severely immunocompromised patient infected with HIV-1.
Schraner C; Hasse B; Hasse U; Baumann D; Faeh A; Burg G; Grimm F; Mathis A; Weber R; Günthard HF
Clin Infect Dis; 2005 Jun; 40(12):e120-4. PubMed ID: 15909255
[TBL] [Abstract][Full Text] [Related]
19. Miltefosine (Impavido): the first oral treatment against leishmaniasis.
Sindermann H; Croft SL; Engel KR; Bommer W; Eibl HJ; Unger C; Engel J
Med Microbiol Immunol; 2004 Nov; 193(4):173-80. PubMed ID: 14513375
[TBL] [Abstract][Full Text] [Related]
20. What steps can be taken to counter the increasing failure of miltefosine to treat visceral leishmaniasis?
Sundar S; Singh A
Expert Rev Anti Infect Ther; 2013 Feb; 11(2):117-9. PubMed ID: 23409817
[No Abstract] [Full Text] [Related]
[Next] [New Search]